Free Trial
NASDAQ:NVCR

NovoCure (NVCR) Stock Price, News & Analysis

NovoCure logo
$12.33 +0.31 (+2.58%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$12.32 -0.01 (-0.04%)
As of 08/29/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NovoCure Stock (NASDAQ:NVCR)

Key Stats

Today's Range
$12.05
$12.47
50-Day Range
$10.90
$18.46
52-Week Range
$10.87
$34.13
Volume
1.01 million shs
Average Volume
1.60 million shs
Market Capitalization
$1.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.79
Consensus Rating
Moderate Buy

Company Overview

NovoCure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

NVCR MarketRank™: 

NovoCure scored higher than 82% of companies evaluated by MarketBeat, and ranked 182nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NovoCure has only been the subject of 3 research reports in the past 90 days.

  • Read more about NovoCure's stock forecast and price target.
  • Earnings Growth

    Earnings for NovoCure are expected to decrease in the coming year, from ($1.30) to ($1.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NovoCure is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NovoCure is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NovoCure has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about NovoCure's valuation and earnings.
  • Percentage of Shares Shorted

    5.27% of the float of NovoCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NovoCure has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NovoCure has recently increased by 5.88%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NovoCure does not currently pay a dividend.

  • Dividend Growth

    NovoCure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.27% of the float of NovoCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NovoCure has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NovoCure has recently increased by 5.88%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    NovoCure has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for NovoCure this week, compared to 5 articles on an average week.
  • Search Interest

    4 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added NovoCure to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NovoCure insiders have bought more of their company's stock than they have sold. Specifically, they have bought $231,800.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.52% of the stock of NovoCure is held by insiders.

  • Percentage Held by Institutions

    84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NovoCure's insider trading history.
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVCR Stock News Headlines

Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
See More Headlines

NVCR Stock Analysis - Frequently Asked Questions

NovoCure's stock was trading at $29.80 on January 1st, 2025. Since then, NVCR stock has decreased by 58.6% and is now trading at $12.33.

NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings data on Thursday, July, 24th. The medical equipment provider reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. The firm's revenue was up 5.6% compared to the same quarter last year.
Read the conference call transcript
.

NovoCure's top institutional shareholders include Soleus Capital Management L.P. (6.18%), Geode Capital Management LLC (2.19%), Balyasny Asset Management L.P. (2.03%) and Marshall Wace LLP (1.27%). Insiders that own company stock include Wilhelmus Cm Groenhuysen, Ashley Cordova, W Anthony Vernon, Frank X Leonard, Christoph Brackmann, Pritesh Shah, Michal Nath Puri, Uri Weinberg, Asaf Danziger and Mukund Paravasthu.
View institutional ownership trends
.

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NovoCure investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Chembio Diagnostics (CEMI), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC).

Company Calendar

Last Earnings
7/24/2025
Today
8/30/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NVCR
CIK
1645113
Fax
N/A
Employees
1,488
Year Founded
2000

Price Target and Rating

High Price Target
$38.00
Low Price Target
$14.50
Potential Upside/Downside
+133.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$168.63 million
Net Margins
-27.13%
Pretax Margin
-22.54%
Return on Equity
-47.74%
Return on Assets
-13.79%

Debt

Debt-to-Equity Ratio
0.28
Current Ratio
1.45
Quick Ratio
1.39

Sales & Book Value

Annual Sales
$605.22 million
Price / Sales
2.28
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.13 per share
Price / Book
3.94

Miscellaneous

Outstanding Shares
111,800,000
Free Float
105,628,000
Market Cap
$1.38 billion
Optionable
Optionable
Beta
0.61

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:NVCR) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners